Discover 275 paid clinical trials in South Dakota. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
South Dakota offers a range of options for both healthy volunteers interested in paid clinical studies and individuals with specific health conditions. Major research hubs in Sioux Falls, Rapid City, and Aberdeen are currently recruiting participants, allowing access to groundbreaking treatments and advanced medical support.
Filter
1
Filter results
Results: 275
Active & Responsive
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
for
Colonic Neoplasms, Neoplasms, Colon
Location: Sioux Falls SD, Grand Island NE, Omaha NE,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18+
Code: NCT05855200
Phase3, Recruiting
Active & Responsive
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
for
Breast Cancer
Location: Sioux Falls SD, Mankato MN, Omaha NE, Lincoln NE,
Sponsor: Stemline Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06492616
Phase3, Recruiting
Active & Responsive
Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Sex: All
Age: 16+
Code: NCT06740526
Phase2, Recruiting
Active & Responsive
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
for
Prostate Cancer Metastatic
Location: Pierre SD, Yankton SD, Sioux Falls SD, Omaha NE,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 0+
Code: NCT06136624
Phase3, Recruiting
Active & Responsive
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
for
Lung Cancer Diagnosis
Location: Pierre SD, Grand Forks ND, Leawood KS, Wichita KS,
Sponsor: Freenome Holdings Inc.
Sex: All
Age: 50+
Code: NCT06122077
Recruiting
Active & Responsive
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
for
PIK3CA Mutation, HER2- Negative Breast Cancer,
Location: Sioux Falls SD, Wichita KS, Dallas TX, Royal Oak MI,